VA Palo Alto Health Care System

Summary

VA Palo Alto Health Care System is a medical facility located in Palo Alto, California. This center is recognized for care of Post-Traumatic Stress Disorder, Depression, Cancer, Insomnia, Lung Cancer and other specialties. VA Palo Alto Health Care System is involved with conducting 299 clinical trials across 432 conditions. There are 30 research doctors associated with this hospital, such as Harlan A. Pinto, Manali I Patel, MD MPH MS, Shipra Arya, MD, and Daniel M. Blonigen, PhD MA.

Top PIs

Clinical Trials running at VA Palo Alto Health Care System

Cancer

Lung Cancer

Ovarian Cancer

Oropharyngeal Carcinoma

Post-Traumatic Stress Disorder

Motor Skills

Peripheral Artery Disease

Non-Small Cell Lung Cancer

Prostate Cancer

Head and Neck Squamous Cell Carcinoma

Immunotherapy + Chemotherapy

for Sarcoma

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.

Recruiting

2 awards

Phase 3

10 criteria

Cetuximab + Pembrolizumab

for Head and Neck Cancer

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.

Recruiting

2 awards

Phase 3

16 criteria

MRI vs. Ultrasound Screening

for Liver Cancer

The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mortality.

Recruiting

1 award

N/A